Keywords: Hyperpolarized MR (Non-Gas), Hyperpolarized MR (Non-Gas)
Motivation: Late-stage renal cell carcinoma (RCC) has poor prognosis, requiring earlier intervention. However, current imaging biomarkers are late indicators of treatment response.
Goal(s): To evaluate hyperpolarised carbon-13 MRI (HP 13C-MRI) in assessing response to neoadjuvant treatment in RCC.
Approach: Four patients with operable RCC underwent HP 13C-MRI and proton (1H) MRI before and after treatment, to evaluate changes in tumour size, LAC/PYR ratio and imaging surrogates for perfusion, hypoxia, and diffusion.
Results: Changes in tumour size were minimal, and 1H-MRI biomarkers showed consistent changes across patients. Changes in LAC/PYR ratio varied across patients and was independent of changes in tumour size and 1H-MRI parameters.
Impact: HP 13C-MRI may be an independent early biomarker for RCC treatment response. Detection of differential metabolic changes before morphological and function changes on MRI may help to tailor treatments earlier, potentially saving lives and reducing costs.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords